Simultaneous discoveries in art and science highlight humanity's shared creativity, problem-solving, and the ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction ...

CRISPR-Cas9 technology – which allows scientists to precisely cut and modify DNA at specific locations within a genome – was discovered by Jennifer Doudna and Emmanuelle Charpentier in 2012.

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...